Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from BriaCell Therapeutics ( (TSE:BCT) ) is now available.
On March 31, 2026, BriaPro Therapeutics filed unaudited condensed interim consolidated financial statements and management’s discussion and analysis for the three- and six-month periods ended January 31, 2026 with securities regulators in British Columbia and Alberta, covering activity in 2025 and 2026. The filings show a small asset base of about $176,890 against current and non-current liabilities totaling roughly $1.8 million, a shareholders’ deficit exceeding $1.6 million, and rising research and development costs that drove comprehensive losses of $227,493 for the quarter and $472,231 for the six months, signaling ongoing funding needs and balance-sheet pressure for stakeholders.
The interim results highlight that BriaPro’s cash position is minimal, its deficit has widened from $1.15 million in July 2025 to $1.62 million by January 31, 2026, and amounts due to related parties have increased to more than $1.6 million. With R&D spending more than doubling year over year and a warrant liability that adds further complexity to the capital structure, the company’s dependence on external financing and related-party support remains a key risk factor for investors and creditors.
The most recent analyst rating on (TSE:BCT) stock is a Hold with a C$5.50 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on BCT Stock
According to Spark, TipRanks’ AI Analyst, BCT is a Neutral.
The score is driven primarily by weak financial performance: no revenue, widening losses, and substantial cash burn that increases funding risk. Technicals add modest pressure given the stock remains below key longer-term moving averages with negative MACD, while valuation offers limited support due to negative earnings and no indicated dividend.
To see Spark’s full report on BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp., through its subsidiary BriaPro Therapeutics Corp., operates in the biopharmaceutical sector, focusing on research and development activities that are typical of early-stage life sciences companies. The business remains in a development phase, funded largely through related-party support and equity-linked instruments, and reports under International Financial Reporting Standards in the U.S. dollar functional currency.
Average Trading Volume: 28,991
Technical Sentiment Signal: Sell
Current Market Cap: C$40.89M
For an in-depth examination of BCT stock, go to TipRanks’ Overview page.